Cardiovascular

CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with ACS

A frequent gene polymorphism affecting the heart-rate response to carvedilol

Impact of genetic polymorphisms SLC2A2 SLC2A5 KHK on metabolic phenotypes

Pharmacogenomic testing and antithrombotic therapy-ready for prime time

Gene-drug interaction in stroke

Clopidogrel- a case for indication-specific pharmacogenetics

Advancing management of hypertension through pharmacogenomics

Impact of ABCC2 ABCG2 and SLCO1B1 polymorphisms on the phamacokinetics of pitavastatin in humans

Association of CYP2C19 genotype with periprocedural myocardial infarction

Cardiovascular pharmacogenomics-current status and future directions

La era de la farmacogenómica - el ejemplo del clopidogrel

The functional G143E variant of carboxylesterase -clopidogrel active metabolite

Pharmacogenomics-increasing the safety and efectiveness of drug therapy

New drugs, procedures, and devices for hypertension

Regresar al Acervo